Citaat | Gerechtshof Den Haag 22 februari 2022

Onder 3.2.4. Gerechtshof Den Haag 22 februari 2022

Een alinea uit Gerechtshof Den Haag 22 februari 2022, ECLI:NL:GHDHA:2022:862.

It has also been unexpectedly discovered that low doses and plasma/plasma/serum levels of desmopressin are pharmacologically active and can achieve desired therapeutic efficacy. The present inventor has found that doses and plasma/plasma/serum concentrations of desmopressin which are from 5 to 40% of the current recommended doses and resulting plasma/plasma/serum levels are therapeutically effective, and in some cases safer for treatment of CDI, PNE, and additional clinical indications requiring pharmacological concentration of the urine. It has been discovered that the actual dose response curve of desmopressin is shifted to the left relative to current theory and practice and that at each plasma/plasma/serum concentration point over the dose range predicted and incremental pharmacological effect in terms of urine concentration is observed.

Zelf controleren

Voor dit citaat hoeft niemand Bron op zijn woord te geloven. Het document dat rechtspraak.nl publiceerde, staat op https://bron.page/api/v1/blobs/ef3ffedeeb9c6ca436cd8e55e0752e7b1908126fe026c623af4ff6f330ea2735. Wie het ophaalt en de SHA-256 ervan berekent, krijgt ef3ffedeeb9c6ca436cd8e55e0752e7b1908126fe026c623af4ff6f330ea2735, en de alinea staat in dat document op bytes 37768 tot 38696.